Analyzing the Metrics of Stocks Advertised on CNBC
Looking into some of the companies advertised on CNBC shows their riskiness for stock investors.
Charles Rotblut
Stock Evaluator: Nexalin Technology, Inc. (NXL)
Nexalin Technology, Inc. NXL
$0.33
0.00
0.45%
August 21, 2026 4:00:00 PM
EST
Volume: 70,616
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Commentary & Analysis
4 Undervalued Advanced Medical Equipment & Technology Stocks for Thursday, March 09
Discover the top 4 undervalued Advanced Medical Equipment & Technology stocks for Thursday, March 09 based on AAII’s Stock Grades.Jenna Brashear
3 Undervalued Advanced Medical Equipment & Technology Stocks for Tuesday, February 07
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Tuesday, February 07 based on AAII’s Stock Grades.Jack Gilleland
4 Undervalued Advanced Medical Equipment & Technology Stocks for Tuesday, January, 03
Discover the top 4 undervalued Advanced Medical Equipment & Technology stocks for Tuesday, January, 03 based on AAII’s Stock Grades.Jenna Brashear
Is Nexalin Technology Inc (NXL) Stock a Good Investment?
Learn more about Nexalin Technology Inc's (NXL) stock grades for Value and Growth and determine whether this Advanced Medical Equipment & Technology stock meets your investment needs.Cynthia McLaughlin
Financial Summary
| Share Statistics | NXL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7.3 | $422.9 | 5% |
|
| Shares Out (Mil) | 21.1 | 41.4 | 31% |
|
| Institutional Ownership | 23.9% | 83.6% | 11% |
|
| Float (Mil) | 19.3 | 34.9 | 28% |
|
| Beta | 4.04 | 0.88 | 99% |
|
| Avg Daily Volume (000s) | 78 | 409 | 32% |
|
| Price Change (52-week) |
(53.9%) | 66.3% | 13% |
|
| Growth | NXL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.4% | 11.9% | 52% |
|
| Net Income (5yr) | (19.3%) | (5.9%) | 21% |
|
| EPS (5yr) | 12.0% | 10.4% | 50 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 0.0% | (16.2%) | 64% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.090) | ($0.380) | ($0.310) | |
| Month Ago EPS | ($0.090) | ($0.380) | ($0.310) | |
| # Rev Up | na | 0 | na | |
| # Rev Down | na | 1 | na | |
| Three Months Ago EPS | ($0.090) | ($0.380) | ($0.310) | |
| Year/Year Chg | (15.1%) | (24.3%) | na | |
| Financials | NXL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $123 | 0% |
|
| Net Income (TTM) (Mil) | ($9) | ($9) | 30% |
|
| EPS (TTM) | ($0.464) | ($0.400) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($3) | 23% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $1 | 45% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $22 | 0% |
|
| Enterprise Value (Q1) (Mil) | $7 | $418 | 6% |
|
| Valuation | NXL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.74 | 3.13 | 76% |
|
| P/E | na | 28.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | NXL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.2% | 58.7% | 92% |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (187.9%) | (12.3%) | 2% |
|
| ROE | (240.3%) | (12.3%) | 3% |
|
| Liabilities to Assets | 49.4% | 46.0% | 41% |
|
| F-Score | 4 | 4 | 33% |
|
Nexalin Technology, Inc. did not pass any screens on 8/21/2026.
